Form PTO-	1449						t of Commerce lemark Office		ocket No. A/JPW/GJG		al No. 37,341
OTP ET				DISC	CLOSU	RE C	CITATION		Baltimore	T	
QGT 9. 4 200		se s	ever	al she	ets if ne	cess	ary) 	Filing Januar	Date ry 4, 2002		1 of 4
3	<i>E</i> /				U.S	. PA	TENT DOCUMENT	rs			
Initial Management	Doc	ume	ent Nu	mber	Date		Name	Class	Subclass	Filing D	
					FORE	IGN	PATENT DOCUMI	ENTS			
	Docu	ıme	nt N	umbe	r Da	ite	Country	Class	Subclass	Tra	nslation
	1									Yes	No
				$\prod$							
		ОТІ	HER I	OCU	MENTS	(Inclu	ding Author, Title, Date	, Pertinen	t Pages, Etc.)		
/D.G./							t, Ariad Pharm 06cv679 (CMH/B		cals, Ind	. v.	Jon W.
							of Hearing, Ari tion 1:06cv679			als,	Inc. V.
							dum Of Law In St lternative For				
	Oppo: Phari (CMH,	mac	ceut	To ical	Plai s, In	nti nc.	ffs' Motion Fo V. Jon W. Dud	or Sum las, Ci	mary Jud vil Acti	gment, on 1:	, Ariac 06cv679
	TO I	nte	erve	ne A	and Fo	or L	nt Regarding E eave To File, Action 1:06cv	Ariad	Pharmaceu		
							Of Filing, Ari tion 1:06cv679			als,	Inc. V.
$\downarrow$	Inte	rve	ene	By E	li Li	.11y	tiffs' Brief i and Company, Action 1:06cv	Ariad	Pharmaceu	o Mo	tion To
/D.G./							iffs' Brief In lternative For				
EXAMINER	/Dav	vid C	Guzo/		DATE	CON	SIDERED 06/1	5/2008			
*EXAMINER: In	itial if cital	tion o	onside of this	red, whe	ther or not th next con	citatio	n is in conformance with MPE cation to applicant.	EP 609: Draw	line through citati	on if not in	onformance

#### Attv. Docket No. Form PTO-1449 Serial No. U.S. Department of Commerce 75723-ZA/JPW/GJG Patent and Trademark Office 10/037.341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 2 of 44 January 4, 2002 U.S. PATENT DOCUMENTS Class Examiner Document Number Date Name Subclass Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS Document Number Date Country Class Subclass Translation Ves No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Opposition To Plaintiffs' Motion For Summary Judgment, Ariad Pharmaceuticals, Inc. V. Jon W. Dudas, Civil Action 1:06cv679 /DG (CMH/BRP) August 28, 2006 Reply Memorandum In Support Of Defendant's Motion To Dismiss, Or. In the Alternative, For Summary Judgment, Ariad Pharmaceuticals, Inc. V. Jon W. Dudas, Civil Action 1:06cv679 October 3, 2006 Order (Defendant's Motion to Dismiss), Ariad Pharmaceuticals, Inc. V. Jon W. Dudas, Civil Action 1:06cv679 October 3, 2006 Order (Eli Lilly & Company's Motion to Intervene), Ariad Pharmaceuticals, Inc. V. Jon W. Dudas, Civil Action 1:06cv679 August 2, 2006 Defendant Eli Lilly And Company's Pre-Trial Brief, Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company, Civil Case 02 CV 11280 RWZ 2006 Plaintiffs' Supplemental Trial Brief, Pharmaceuticals, Inc. V. Eli Lilly and Company, Civil Case 02 CV 11280 RWZ September 11, 2006 Plaintiffs' Proposed Findings of Fact and /D.G. Conclusions of Law on the issues of Inequitable Conduct,

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

06/15/2008

DATE CONSIDERED

EXAMINER

/David Guzo/

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket 00373 Seria Und 636 75723-ZA/JPW/GJG 10/037 341 10/037,341 Applicants David Baltimore et al. Filing Date

Page 3 of 44

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

	(00000000000000000000000000000000000000		January 4, 2002				
		U.S. PA	TENT DOCUMEN	NTS			
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing D	
	1	FOREIGN	PATENT DOCUM	MENTS			
	Document Number	Date	Country	Class	Subclass	Trai	slation
						Yes	No
	OTHER DOCUM	ENTS (Inclu	ding Author, Title, Da	ate, Pertinen	t Pages, Etc.)		
/D.G./	Indefiniteness, Matter, Ariad Civil Case 02 (	Pharmace	euticals, Inc				
	September 11, 2 And Conclusions §101, (2) Uner Unenforceabilit Inc. V. Eli Li	Of Law forceab y For P	Relating To ( ility For Ind rosecution La	1) Inva equitabl ches, A	lidity Und .e Condu .riad Phan	der 35 nct, <i>P</i> cmaceu	U.S.C. And (3) ticals,
	September 29, 2 of Fact And Con Under 35 U.S.C. Laches, Ariad Civil Case 02 (	clusions §010, (: Pharmace	s of Law On th 2) Inequitable euticals, Inc	e Issue: e Conduc	s of (1) E t, and (3)	Patent Pros	ability ecution
	September 29, 2 of Facts And Co Eli Lilly and C	onclusio	ns of Law, A	riad Pha	rmaceutio		
	April 20, 2000 Invalidity An Pharmaceuticals	d Non-	Infringement	, Amge			
/D.G./	April 20, 200 Pharmaceuticals	06 Civi s, Inc.,	l Cover She Civil Action	eet, An	igen, Inc	. V.	Ariac
EXAMINER	/David Guzo/	DATE CON	SIDERED 06/1	5/2008			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

10037341 - GALL: 1636

## Form PTO-1449

## U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 75723-ZA/JPW/GJG

Serial No. 10/037,341

# INFORMATION DISCLOSURE CITATION

Applicants
David Baltimore et al

	INF	O	RIV.	IAT	П	ON	DIS	CI	LOSURE C	CITATION	David Baltimore et al.					
			π	se s	se	vera	al sh	ieet	ts if necessa	ary)	Filing Januar	Date y 4, 2002		4 of		
									U.S. PA	TENT DOCUMEN	TS					
Examiner Initial			Do	cum	en	t Nu	mbe	-	Date	Name	Class	Subclass	Filing D			
			Г	Г	Γ	Т	Т	Г	1			1				
		-		_	_	_	_	۰.	L	D A COUNTY DO CALLY C	DAIMO.	1				
	_	_	_		_			_	1	PATENT DOCUM	1	1	_			
1		D	ocı	ume	en	t N	ımt	er	Date	Country	Class	Subclass	Tra	nslation		
	l												Yes	No		
				Г	Г	T	Т	Π								
			_			ED F			ENTE (I I -	dina Anakan Tida Dad	. Dentines	1 P E4-)	-	<u> </u>		
			_							ding Author, Title, Dat on The Filing o						
/D.G./		Re	ga	rd:	ir	ng	a		Patent	or Trademark	, Amg	en, Inc.	. V.			
		a V. Ju A-	Cl A ne D)	airi.	a .	, A d P	nd hai	Fa	ailure T aceutica Declarat:	ject Matter Ju o Join Indispe ls, Inc., Civi  ion of Laurie iad Pharmaceut	ensable l Actio	Parties, on 06-259	Amge -KAJ ling E	en, Ind		
		Me Su Re (i	mc bj li nc	eci ef	no t N	dum Ma May ing	of tte Be	r er e G	aw In Su Jurisdi Granted,	nt Ariad Phar apport Of Its M ction, Failure And Failure T gen, Inc. V. A J	otion ' To St o Join	To Dismiss ate A Cla Indispens	s For im Fo	Lack or whice Partie		
$\downarrow$		20	06	, 1	Aπ		n,	Ιn	c. V. Ar	ion of Paul Ca iad Pharmaceut						
/D.G./	- 1	A-	L)	, 7	٩n		n,	Ιn	c. V. Ar	on of Melanie						
EXAMINE	R		- /	Dav	⁄id	Gu	20/		DATE CON	SIDERED	06/15/200	08				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. Serial No. 75723-ZA/JPW/GJG 10/037,341

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Applicants David Baltimore et al.

	(1	Use s	sever	al shee	ets if necess	ary)	Filing Janua:	Date ry 4, 2002	Page	5 of 44			
					U.S. PA	TENT DOCUME	NTS						
Examiner Initial	Do	cum	ent Nu	ımber	Date	Name	Class	Subclass	Filing D	ate opriate			
				1									
					FOREIGN	PATENT DOCUM	MENTS						
	Doc	ume	nt N	umber	Date	Country	Class	Subclass	Tra	nslation			
									Yes	No			
	$\dashv$	Т	П	ТТ		<b> </b>		1	1.03	110			
						l iding Author, Title, D			<b>.</b>	L			
/D.G./	June For	) , A 5-c 2 2 8 Lac	Amge v-25 3, 2 ck o	en, Ir 59 (K 1006 I f Sub	nc. V. Ar AJ) Plaintiff	ion of Frank iad Pharmaceu fs' Opposition ter Jurisdict	To Ari	Inc., Civ	on To	Dismiss Claim,			
	unre Civ:	And Failure to Join Indispensable Parties (including Exhibits Aunreported cases), Amgen, Inc. V. Ariad Pharmaceuticals, Inc. Civil Action 06-259-KAJ  July 12, 2006 Declaration of Fritz Casselman, Amgen, Inc. V. Aria Pharmaceuticals, Inc., Civil Action 06-259-KAJ											
						on of Patrici Civil Action			Inc.	/. Ariad			
<b>\</b>	Memo Sub Rel:	oran ject ief	ndum t Ma Ma	n of i atter ny Be	Law In Su Jurisdi Grante	ant Ariad Phupport of its ction, Failured, And Fail Amgen, Inc.	Motion e to St	to Dismis ate a Cla	s For	Lack of r Which			
/D.G./						ntal Declarat outicals, Inc.							
EXAMINER	. //	Davio	d Guz	o/ -	DATE CON	SIDERED 06	5/15/2008						

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

### Form PTO-1449 U.S. Department of Commerce

EXAMINER

/David Guzo/

Patent and Trademark Office

Atty. Docket No. Seri 75723-ZA/JPW/GJG 10/0 10/037,341 Applicants

David Baltimore et al. Page 6 of 44

## INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

January 4, 2002 U.S. PATENT DOCUMENTS

Filing Date

Examiner Initial	Document !	Number	Date	Name	Class	Subclass	Filing Da	
		F	OREIGN	PATENT DOCUM	MENTS		1	
	Document	Number	Date	Country	Class	Subclass	Tran	slation
							Yes	No
	OTHE	R DOCUM	ENTS (Inclu	ding Author, Title, Da	te, Pertinen	t Pages, Etc.)		
/D.G./	Proposed Pharmace			rial Order, Civil Action			v.	Ariad
	July 19 Pharmace			eduling Orde Civil Action			. v.	Ariac
				Management O			c. V.	Ariad
	Young Co	naway	Stargat	to Judge Jord t & Taylor, Civil Action	LLP, A	Amgen, In		
		eddes,	Amgen,	to Judge Jord Inc. V. Ariad				
$\downarrow$	Ashby & (	Geddes	(includ	to Judge Jor ing Exhibits Civil Action	A & B),	Amgen, 1	J. Ba	lick of . Ariac
/D.G./	Young Cor	naway S	targatt	to Judge Jor & Taylor, LLM harmaceuticals	P (incl	uding Exhi	bits	1 & 2),

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

06/15/2008

DATE CONSIDERED

U.S. Department of Commerce

Patent and Trademark Office

Atty. Docket:00373 Ser. 1AUN-636 75723-ZA/JPW/GJG 10/037 241 10/037,341

## INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Applicants David Baltimore et al. Filing Date
January 4, 2002 Page 7 of 44

Examiner	Docume	ent N	iumb	er	Date	Name	Class	Subclass	Filing D				
nitial	are in		- 1	1	100	_ 8-15			if Appro	priate			
		ш	_	F	ORFICNI	PATENT DOCU	MENTS	1	1				
	Docume	ent l	Num		Date	Country	Class	Subclass	Trai	nslation			
									Yes	No			
						ling Author, Title, l							
/D.G./					2006 Orde	er, Amgen, 1 259-KAJ	Inc. V. A	Ariad Phai	cmaceu	ticals			
	Certif:	ica	tio	n P	ursuant	ndant Ariad to 28 U.S.C. Civil Actio	§1292(b)	), Amgen,					
	Memorandum of Law In Support of Its Motion For Certificatio Pursuant To 28 U.S.C. §1292(b), Amgen, Inc. V. Aria Pharmaceuticals, Inc., Civil Action 06-259-KAJ												
		ant	, ,	Amg	en, Inc.	riad Pharma V. Ariad							
	Septeml Support	oer ber	- 25 f A	Amg 9-1 5, ria 28	2006 Dec d Pharma U.S.C.		Pharmace f Elizab inc.'s Mo ncluding	euticals,  eth L. R tion For ( Exhibits	osenb Certif	latt lication			
/D.G./	Septeml Support Pursual Inc. V	ber	f A: To	Amg 9-F 5, ria 28 d l	2006 Decd Pharmacu.S.C.	V. Ariad claration o ceuticals, I §1292(b) (ir.	f Elizab fnc.'s Moncluding c., Civil	eeth L. R tion For ( Exhibits Action 0	osenb Certif A-Q), 6-259-	latt lication  Amgenta			

### U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. Serial No. 75723-ZA/JPW/GJG 10/037,341

Applicants
David Baltimore et al.

David Baltimore et al.
Filing Date Page 8 of 44

# INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

January 4, 2002 U.S. PATENT DOCUMENTS Examiner Document Number Date Name Class Subclass Filing Date Initial f Appropriate FOREIGN PATENT DOCUMENTS Document Number Date Subclass Translation Country Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) October 10, 2006 Plaintiffs' Memorandum in Opposition To Ariad's Motion For Certification Pursuant to 28 U.S.C. §1292(b), Amgen, /D.G./ Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ October 10, 2006 Amgen Appendix of Exhibits 1-2 To Pliantiffs' Memorandum in Opposition To Ariad's Motion For Certification 28 U.S.C. §1292(B), Amgen, Inc. Pharmaceuticals, Inc., Civil Action 06-259-KAJ October 12, 2006 Order, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ October 17, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Reply Memorandum of Law In Support Of Its Motion For Certification Pursuant To 28 U.S.C. §1292(b), Amgen, Inc. V. Pharmaceuticals, Inc., Civil Action 06-259-KAJ November 3, 2006 Order, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ July 7, 2006 Plaintiffs' First Set of Interrogatories Defendant, Amgen, Inc. V. Ariad Pharmaceuticals, Inc., Civil Action 06-259-KAJ July 7, 2006 Plaintiffs' First Set of Requests for Production of Documents and Things to Defendant. Amgen, Inc. V. Ariad /D.G./ Pharmaceuticals, Inc., Civil Action 06-259-KAJ EXAMINER DATE CONSIDERED 06/15/2008 /David Guzo/ EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 75723-ZA/JPW/GJG Serial No. 10/037,341

11	NFORMAT	TION DISC	LOSURE C	Applicants David Baltimore et al.										
		several shee			Filing Januar	Date y 4, 2002	Page 2	9 of 44						
			U.S. PA	TENT DOCUMEN	TS									
Examiner Initial	Docum	ent Number	Date	Name	Class	Subclass	Filing D	ate priate						
		DE LA COMP	,				-							
		]	FOREIGN	PATENT DOCUM	ENTS			. 1						
	Docume	ent Number	Date	Country	Class	Subclass		nslation						
						-	Yes	No						
	سللك		<u> </u>					L						
				ding Author, Title, Dat										
/D.G./				's Rule 26(a)(: uticals, Inc.,										
	Rule	of Civi	1 Proce	s' Initial Dis edure 26(a)(1 Civil Action	), Am	gen, Inc		Federal Ariac						
	August 7, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Response And Objections to Plaintiffs' First Set of Requests For Productio of Documents and Things to Defendant, Amgen, Inc. V. Aria Pharmaceuticals, Inc., Civil Action 06-259-KAJ													
	Supple	mental Re	esponses Production	endant Ariad P And Objection on of Document harmaceuticals	s To Pl	aintiffs' Things t	First o Def	Set of endant,						
	And O	bjection ogatorie:	s To I	nt Ariad Pharm Plaintiff Amg Defendant, Civil Action	en, In Amgen	nc.'s Fi , Inc.	rst	Set of						
/D.G./				endant Ariad P and Objections										
EXAMINER	/David G	Buzo/	DATE CON	SIDERED 06/1	5/2008									
			•											

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

### U.S. Department of Commerce Patent and Trademark Office

Atty Docket No. 75723-ZA/JFW/GJG 10/037,341
Applicants
David Baltimore et al.

	INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)								Applicants David Baltimore et al.					
			(U	se :	sev	eral	she	et.	s if necessa	ary)	Filing Januar	Date y 4, 2002		10 of
									U.S. PA	TENT DOCUMENT	rs			
Examine r Initial			Doc	um	ent	Num	ber		Date	Name	Class	Subclass	Filing D	ate opriate
				L	L									
								F	OREIGN	PATENT DOCUM	ENTS			
		D	ocu	ıme	ent	Nui	mbe	r	Date	Country	Class	Subclass	Tra	nslation
													Yes	No
				Γ							1			
			_	ОТ	HE	R DO	CU	M	ENTS (Inclu	ding Author, Title, Date	e. Pertinen	t Pages, Etc.)		
- /D.G./			ġе.							on of Document harmaceuticals				
		Su Fi	pp rs	le:	me: Se	nta t c	1 F	Re In	sponses iterroga	ndant Ariad Ph and Objection tories to Defe Civil Action	s to Pl endant,	aintiff A Amgen, I	mgen,	Inc.'s
		Ru	le		of	E	Civ	νi	1 Proc	lated Protection cedure 26(c), Civil Action	Amge	en, Inc.	t To V.	
		Įσο	rd	an	, 1	U.S	.D	. c		one Conference gen, Inc. V. A J				
		Jo	rda	an	, 1	U.S	.D	. c		otions Hearing gen, Inc. V. A J				
/D.G./		υ.	S.I	D. 0	c.:		A	mg	gen, Ind	n Hearing befor				
EVAMINI	r D	L						_	DATE CON	CIDEDED 00				

EXAMINER

/David Guzo/

DATE CONSIDERED

06/15/2008

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PT	O-144	9 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 75723-ZA/JPW/GJG	Serial No. 10/0	37,341
INFORM	IATIO	ON DISCLOSURE CITATION	Applicants David Bal	imore et al.	
		s if necessary)	Filing Date January 4, 2002	Page 11 of 44	
		NON PATENT LITERATURE D	OCUMENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title item (book, magazine, journal, serial, symposium, catalog, publisher, city and/or country w	etc.) date, page(s), volumeiss		T2
/D.G./		January 22, 2007 Declaration of El Support of Ariad Pharma., Inc.'s N Pending Conclusion of Reexaminal Patent and Trademark Office, Amg Pharma., Inc., CA No. 06-259-***	Motion to Stay Lation Proceedings en, Inc. et al. (MPT)	itigation s in the v. Ariad	
		January 23, 2007 Defendant Ariad I Stay Litigation Pending Concle Proceedings in the Patent and T Inc. et al. v. Ariad Pharma., (MPT)	usion of Reexa rademark Office	mination , Amgen,	
		January 23, 2007 Defendant Ariad Memorandum of Law in Support Litigation Pending Conclusion of F in the Patent and Trademark Offic G), Amgen, Inc. et al. v. Ariad F 259 *** (MPT)	of Its Motion Reexamination Pro e (including Ext	to Stay oceedings nibits A-	
		January 31, 2007 Plaintiffs' Fir Admission to Defendant, Amgen, Pharma., Inc., CA No. 06-259 (***	Inc. et al.	v. Ariad	
		February 20, 2007 Transcript of before Hon. Mary Pat Thynge, U.S. Inc. et al. v. Ariad Pharma., Inc	Magistrate Judge c., CA No. 06-25	e, Amgen, 9 (***)	
		February 22, 2007 Defendant Aria Set of Requests for Production of et al. v. Ariad Pharma., Inc., CA	E Documents, Amo A No. 06-259-MPT	en, Inc.	
		February 22, 2007 Defendant Aria Set of Interrogatories, Amgen, Pharma., Inc., CA No. 06-259-MPT	Inc. et al.	v. Ariad	
		March 7, 2007 Defendant Ariad Phand Objections to Plaintiffs' Fadmission to Defendant, Amgen, Pharma., Inc., CA No. 06-259-MPT	rst Set of Requ Inc. et al.	ests for v. Ariad	
$\downarrow$		March 26, 2007 Plaintiffs' Respon Set of Requests for Production of et al. v. Ariad Pharma., Inc., Ch	E Documents, Amo A No. 06-259-MPT	en, Inc.	
/D.G.	./	March 26, 2007 Plaintiffs' Responsible Ariad's First Set of Interrogator	cies, Amgen, Inc		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line throughstinn if not in conformance and not considered. Include copy of this form with next communication to applicathapplicant's unique citation designation number (optional)Applicant is to place a checkmark here if English language Translation is attached

06/15/2008

/David Guzo/

EXAMINER

SIGNATURE

			1003	7341 - GAI	J: 160
Form PT	O-144	9 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 75723-ZA/JPW/GJG	Serial No. 10/0	37,341
INFORM	IATIO	N DISCLOSURE CITATION	Applicants David Bal	timore et al.	
		s if necessary)	Filing Date January 4, 2002	Page 12 of 44	
		NON PATENT LITERATURE DO	CUMENTS		
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of item (book, magazine, journal, serial, symposium, catalog, et publisher, city and/or country who	c.) date, page(s), volumeiss		T <sup>2</sup>
/D.G./		(Technology Tutorial), Amgen, I Pharma., Inc., CA No. 06-259-MPT	nc. et al.		
		April 3, 2007 Notice of Filing of (Plaintiffs' Technology Tutorial), Ariad Pharma., Inc., CA No. 06-259	Amgen, Inc. o	et al. v.	
		April 3, 2007 Notice of Filing o (including Tabs A and B), Amgen, Pharma., Inc., CA No. 06-259-MPT	Inc. et al.	v. Ariad	
		April 3, 2007 Ariad Pharma., Inc Amgen, Inc. et al. v. Ariad Pharma MPT	., Inc., CA No	. 06-259-	
000000000000000000000000000000000000000		April 12, 2007 Defendant Ariad I Supplemental Responses and Objectic Set of Interrogatories to Defendant Ariad Pharma., Inc., CA No. 06-259	ns to Plaintif ., Amgen, Inc.	fs' First	
		April 13, 2007 Amended Complaint for Patent Invalidity and Non-Infribal. v. Ariad Pharma., Inc., CA No.	ngement, Amgen		
***************************************		April 13, 2007 Second Amended Com Judgment of Patent Invalidity and Unenforceability, Amgen, Inc. et Inc., CA No. 06-259-MPT	Non-Infringer	ment, and	
		April 13, 2007 Answer to Amended (and Demand for Jury Trial, Amgen, Pharma., Inc., CA No. 06-259-MPT	Inc. et al.	v. Ariad	
		April 17, 2007 Letter to Judge Balick, Esq., Amgen, Inc. et al. v CA No. 06-259-MPT	v. Ariad Pharm	a., Inc.,	
		April 19, 2007 Defendant and (Ariad's Second Set of Requests for to Amgen, Amgen, Inc. et al. v. A No. 06-259-MPT	Production of riad Pharma.,	Documents	
$\downarrow$		April 20, 2007 Defendant Ariad Supplemental Responses and Objectic Set of Requests for Admission to De al. v. Ariad Pharma., Inc., CA No.	ns to Plaintif fendant, Amgen		
/D.G./		April 23, 2007 Plaintiffs' First and Objections to Ariad's First S Amgen, Inc. et al. v. Ariad Pharma MPT	Supplemental I et of Interro	gatories,	

SIGNATURE \*EXAMINER: Initial if citation considered, whether or not citation inkonformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant/splicant's unique citation designation number (optional)Applicant is to place a theckmarkfere if English language Translation is attached.

06/15/2008

EXAMINER

· /David Guzo/

Form PT	O-144	9 U.S. Department of Commerce		7341 - GAI	
FUILLE	O-144	Patent and Trademark Office	75723-ZA/JPW/GJG	Derial No. 10/0	,57,541
INFORM	IATIO	N DISCLOSURE CITATION	Applicants David Balt	imore et al.	
(Use severa	l sheets	if necessary)	Filing Date January 4, 2002	Page 13 of 44	
		NON PATENT LITERATURE DOC	UMENTS		
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of th item (book, magazine, journal, serial, symposium, catalog, etc.) publisher, city and/or country wher	date, page(s), volumeiss:		T <sup>2</sup>
/D.G./		May 1, 2007 Amgen's Technology Tut al. v. Ariad Pharma., Inc., CA No.		Inc. et	
		May 1, 2007 Ariad Pharma., Inc. Amgen, Inc. et al. v. Ariad Pharma. MPT	, Inc., CA No.	06-259-	
		May 1, 2007 Transcript of Tutoria Mary Pat Thynge, U.S. Magistrate Jud v. Ariad Pharma., Inc., CA No. 06-2	lge, Amgen, Ind		
		May 3, 2007 Amgen Entities' Reply to and Whitehead's Counterclaim, Amgen Pharma., Inc., CA No. 06-259-MPT			
		Bottero et al. (2006) "NF-kB an hematopoiesis," <i>Cell Death and Difi</i> 797			
$\downarrow$		Doucas et al. (2000) "Cytoplasmic protein kinase A mediates cross-re the glucocorticoid receptor," PNAS,	pression by N 97(22): 1189	F-κB and 3-11898	
/D.G./		Withoff, S. et al. "Regulating the M From Natural Strategies to Superdrugs." in: Ghosh, S., Handk Factor NF-kappaB (Boca Raton, FL, 195-211	Rationally book of Trans	Designed cription	

\*EXAMINER: Initial if citation considered, whether or not tation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant/splicant's unique citation designation number (optional)Applicant is to place a checkmark here it fenglish language Translation is statched.

06/15/2008

EXAMINER

SIGNATURE

/David Guzo/

#### 10037341 - GAU: 1636 Serial No. Form PTO-1449 Attv. Docket No. U.S. Department of Commerce 75723-ZA/JPW/GJG 10/037.341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 14 of January 4, 2002 44 U.S. PATENT DOCUMENTS Document Number Date Class Subclass Filing Date Examiner Name Initial f Appropriate FOREIGN PATENT DOCUMENTS Subclass Document Number Date Country Class Translation Yes Nο OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Berry et al., "lα, 25-Dihydroxyvitamin D, Stimulates Phyophorylation of IkBα and Synergizes with TPA to Induce Nuclear Translocation of NFkB during Monocytic Differentiation /D.G./ of NB4 Leukemia Cells, Experimental Cell Research 272, 176-184 (2002) Lepper et al., "Clinical implications of antibiotic-induced endotoxin release in septic shock", Intensive Care Med (2002), 28:824-833 /D.G./ Shenep and Mogan, "Kinetics of Endotoxin Relaese During Antibiotic Therapy For Experimental Gram-Negative Bacterial /D.G./ Sepsis", The Journal of Infectious Diseases, Vol. 150, No. 3, (1984) 380-388 July 6, 2007 Finding of Facts And Conclusions of Law, Ariad Pharamaceuticals, Inc. v. Eli-Lilly & Co., U.S. District Court, District of Massachusetts, CV-02-11280-RWZ /D.G./

/David Guzo/ EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

06/15/2008

DATE CONSIDERED

EXAMINER

#### Atty. Docket No. 75723-ZA/JPW/GJG Serial No. Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office 10/037,341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. Page 15 of 44 (Use several sheets if necessary) Filing Date January 4, 2002 U.S. PATENT DOCUMENTS Examiner Document Number Date Name Class Subclass Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS Document Number Class Subclass Translation Date Country Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) April 17, 2007 Deposition of Harvey J. Berger, M.D., Amgen, Inc. /D.Gl/ et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT April 20, 2007 Videotaped Deposition of Chen-Ming Fan, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT April 24, 2007 Videotaped Deposition of Jonathan H. Lebowitz, Ph.D., Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT April 27, 2007 Videotaped Deposition of Harinder Singh, Ph.D. Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT May 3, 2007 Videotaped Deposition of Ranjan Sen, Ph.D., Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civill Action No. 06-259-MPT May 16, 2007 Videotaped Deposition of Phillip A. Sharp, Ph.D.,

/David Guzo/ EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conforman and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

Civil Action No. 06-259-MPT

Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del.

06/15/2008

/D.G./

EXAMINER

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

<del>141 - GAU: 163</del>6 Serial No. Atty. Docket No. 75723-ZA/JPW/GJG 10/037,341

Applicants

David Baltimore et al. Filing Date Page 16 of 44 January 4,

							U.S. PA	TENT DOCUMEN	rs			
Examiner Initial		Do	cum	ent Nu	mbe	r	Date	Name	Class	Subclass	Filing D	ate opriate
						F	OREIGN	PATENT DOCUM	ENTS			
	I	)ocı	ıme	nt N	umb	er	Date	Country	Class	Subclass	Tra	nslation
											Yes	No
										1		
			от	HER	DOC	UM	ENTS (Inclu	ding Author, Title, Dat	e, Pertinen	t Pages, Etc.)		
/D.G./	Pl	h.D	٠.	Amo	en,	I	nc. et a	ed Deposition al. v. Ariad Pl o. 06-259-MPT				
	Αī	nge	n,	Inc	. е	t	ideotape al. v. A o. 06-25	d Deposition o riad Pharmaceu 9-MPT	f Mich	ael J. Le , Inc. et	nardo al.;	, M.D., D. Del.
	Sı	ipp nte	le	nent	al ori	Re	sponses To De	nt Ariad Phan and Objections efendant, Amge et al., D. Del.	To Plant	aintiffs' c. et al	First	Set Of
<b>1</b>	S1 Re	agu	ler est	nent	al or	Re Ad	sponses mission	nt Ariad Phar And Objections To Defendant, et al., D. Del.	To Pla Amgen,	intiff's Inc. et	First	Set of . Ariad
/D.G.,	Co	ona	way	y Si	ar	gat	tt & Ta	Judge Thynge fi ylor, LLP, Am et al., D. Del.	gen, I	nc. et a	1. v	. Ariad
	$\vdash$	_					-					
EXAMINER	/Da	vid (	31171	n/			DATE CON	SIDERED 06/15/2	2008			

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTC	D-144	19						nt of Commerce demark Office	Atty. Doci	10037 ket No. A/JPW/GJG	Serial 10/037	
	INFC							CITATION	Applicants David B	s Baltimore et a	al.	
<u></u>		(U	Jse s	severa	l sh	eet _	ts if necessa	ary)	Filing Dat January	te y 4, 2002	Page 1	17 of <b>44</b>
		_	_		_	_	U.S. PA	TENT DOCUMEN	TS			
Examiner Initial	$\downarrow$	Do	cume	ent Nun	ıber	_	Date	Name	Class	Subclass	Filing D	
$\longrightarrow$	+	+	┦	+	$\vdash$	$\vdash$		<b></b>	+-	+	-	
		_	ш	ш	ш	F	OREIGN	PATENT DOCUM	ENTS	L		
	I	Doc	ume	ent Nu	nt Number Dat			Country	Class	Subclass	Tra	nslation
	$\perp$					_					Yes	No
	$\dashv$	Ţ	$\square$	$\prod$	Ц	Ĺ						
	丄	$\perp$	پـــ	Щ	Ц	L	<u> </u>	<u> </u>			لــــــــــــــــــــــــــــــــــــــ	
								uding Author, Title, Date			- 1 -1- 4	b.b.
/D.G./	&	Ge	edde	es, 2	Amg	gen	n, Inc.	Judge Thynge fi et al. v. Ari ion No. 06-259	iad Pha:	rmaceutic	als,	f Asnby
		- 70				_	-th/a	To he			10	7-0
/D.G./	Ma Of Re	ass f H ese	ach Harv	huset vard ch's	c Co	1: 011 Cou	nstitute lege, an untercla	Reply To Ar e of Technology nd The Whitehe aim, Amgen, et al., D. Del.	ry, The ead Inst Inc.	President titute fo et al.	t And or Bio	Fellows medical Ariad
	+						Pn	- initial Second	· 2	1 F		700
/D.G./	01 6	bje &:	cti 12,	ions , Amg	To jen,	A:	riad's F Inc. et	ntities' Second First Set of In al. v. Ariad P o. 06-259-MPT	nterroga	atories: 1	NOS. 1	L, 2, 5,
/D.G./								"Modes of act: USA (1985) 82			like	drugs",
			÷		<u> </u>	_		00 (				

EXAMINER

/D.G./

/David Guzo/

Acta. (1991) 1072:63-80

DATE CONSIDERED

06/15/2008

Baeuerle, P.A., "The Inducible Transcription Activator NF-kB: Regulation by Distinct Protein Subunits", Biochimica Biophysica.

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

orm PT	O-1	449							t of Commerce lemark Office	Atty. Doci 75723-Z.	tet No. 4/JPW/GJG	Serial 10/037	
	INI	FOI	RM	ATIO	N:	DIS	CL	OSURE C	CITATION	Applicant David B	altimore et a	ıl.	
			(U	se sev	era	l sh	eet:	s if necessa	ary)	Filing Dat January		Page 1	.8 of 4
								U.S. PA	TENT DOCUMEN	NTS			
xaminer iitial			Doc	ument	Nun	nber		Date	Name	Class	Subclass	Filing D	
						⊢						-	
		ш		LI		ш	F	OREIGN	PATENT DOCUM	MENTS	I	L	
		D	ocu	ment	ent Number			Date	Country	Class	Subclass		nslation
		L,			_	_					ļ	Yes	No
		Н	Н	$\vdash$	_	$\perp$				_			
		Н		-	Ͱ	-							
		Ш	Ш		L_				ding Author, Title, Da				
/D.G./		In Hi:	ld te:	win, ract	W: pat	.S ith	. , a	"Two ' Single	Transcription Regulatory S plex Promoter"	Factor equence	s, NF-xB	lass	I majo
/D.G./		Sy	ntl		s:	Me			ontrol of Cach of Endotoxin				
/D.G./		St:	rai	inska nded 997-:		Pho			Regulation of oate Oligonu			with ence	
/D.G./		re fa	ce <sub>l</sub>	ptor	α)	cha in	air Cu	expres	"Cyclosporin assion by affect human T lymph	ting act	civation o	of NF-	κB-lik

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

/D.G./

/David Guzo/

Chedid, M. And Mizel, S.B., "Involvement of Cyclic AMP-Dependent Protein Kinases in the Signal Transduction Pathway for Interleukin-1" Molecular And Cellular Biology (1990) 10:3824-3827

06/15/2008

										10027	72/11	GAU: 16
Form PTC	<b>)-144</b>	9						t of Commerce lemark Office	Atty. Doci		Serial 10/037	No.
,	NFO	RMA	TIC					CITATION	Applicant David Ba	s altimore et al.		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
		(Use	sev	era	l sh	eet:	s if necessa	ary)	Filing Dat			19 of 44
							U.S. PA	TENT DOCUMEN	ITS			
Examiner Initial		Docui	nent	Nun	ıber		Date	Name	Class	Subclass	Filing D	
								1				
						F	OREIGN	PATENT DOCUM	1ENTS			
	D	ocun	ent	Nu	mb	er	Date	Country	Class	Subclass	Tra	nslation
							Date Country			Yes	No	
		П			П	П						
		П		П	П	П						
		П			П							
		0	THE	R D	oct	JM	ENTS (Inclu	ding Author, Title, Da	te, Pertinen	t Pages, Etc.)		
/D.G./	Μe	land	oma	: T	he	P	resence	1, 25-Dihydro of Receptors ogy (1981) 108	and Inh	ibition o	nd Ma f Cell	lignant Growth
/D.G./								F-κB Activati Signal" Scie				
70.03												
/D.G./	an	ino	sa	lio	cy1	Lic		of remission i in high dose: 24				
- 1	Þс	bri]	lla	, (	G.	e	t al.,	"Is Ethanol	Metabol	ism Affec	cted	by Oral

Administration of Cimetidine and Ranitidine at Therapeutic Doses?

Eck, S.D. et al., "Inhibition of Phorbol Ester-Induced Cellular Adhesion by Competitive Binding of NF-kB In Vivo" Molecular and

06/15/2008

Hepato-gastorenterol (1984) 31:35-37

Cellular Biology (1993) 13:6530-6536

/David Guzo/

and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance

/D.G./

/D.G./

EXAMINER

#### 10037341 - GAU: 1636 Atty. Docket No. Form PTO-1449 Serial No. U.S. Department of Commerce 75723-ZA/JPW/GJG 10/037.341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 20 of 44 January 4, 2002 U.S. PATENT DOCUMENTS Date Class Subclass Filing Date Examiner Document Number Name Initial f Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Subclass Translation Date Country Class Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Edbrooke, M.R. et al., "Identification of cis-Acting Sequences Responsible for Phorbol Ester Induction of Human Serum Amyloid / Gene Expression via a Nuclear Factor KB-Like Transcription Factor" /D.G./ Molecular and Cellular Biology (1989) 9:1908-1916 Emmel, E.A. et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation" Science (1989) /D.G./ 246:1617-1620 Giri. J.G. et al.. "Interleukin 1-Mediated Induction of K-Light Chain Synthesis And Surface Immunoglobulin Expression of Pre-B Cells" The Journal of Immunology (1984) 132:223-228 /D G / Gray, T.K. et al., "17β-Estradiol acts directly on the clonal osteoblastic cell line UMR106" Proc. Natl. Acad. Sci. USA (1987) /D.G./ 84:6267-6271 Griffith [1], B.P., et al., "Targeted blood levels of cyclosporine for cardiac transplantation" J. Thorac Cardiovasc Surg (1984)

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

al.,

Cyclosporin A and Prednisone" Ann. Surg. (1982) 196:324-329

06/15/2008

"Cardiac Transplantation with

B.P., et

DATE CONSIDERED

88:952-957

/David Guzo/

Griffith

[2],

/D.G./

/D.G./ EXAMINER

U.S. Department of Commerce Patent and Trademark Office

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Atty. Docket No 75723-ZA/JPW/GJG 10/037,341

Applicants David Baltimore et al. Filing Date

	(Use se	ver at sheet	s ii necessa	ary)		y 4, 2002		21 of 44				
			U.S. PA	TENT DOCUMEN	TS							
Examiner Initial	Documen	t Number	Date	Name	Class	Subclass	Filing D					
					<u> </u>							
		F	OREIGN	PATENT DOCUM	ENTS							
	Documen	t Number	Date	Country	Class	Subclass	Tra	nslation				
							Yes	No				
	ОТН	ER DOCUM	ENTS (Inclu	ding Author, Title, Dat	e, Pertinen	t Pages, Etc.)						
/D.G./	Infection	ons And	Post-St	ffect of Corti creptococcal Co 50) pp. 274-28	omplica							
/D.G./	Holick, M.F. et al., "Identification of 1,25- Dihydroxycholecalciferol, a Form of Vitamin D, Metabolically Active in the Intestine" Proc. Nat. Acad. Sci. USA (1971) 68:803- 804											
/D.G./	the Reg		of Huma	oa B-Specific D an Interleukin								
/D.G./				ion Half-life ogy (1987) 60:			ng Ha	ngover"				
/D.G./	the Mit	ogenic A .dermal	ctivity Growth	amethasone Inh of Tumor Necr Factor in Hum 987) 132:271-2	rosis F man Fib	actor, In	terle	ukin-1,				
/D.G./	Recepto:	r Expre	ssion i	"Inhibitors of n Human Leuk 986) 103:469-4	emic T			nd IL-2 Jurkat'"				
EXAMINER	/David Guzo	/	DATE CON	SIDERED 06/	15/2008							
EXAMINER:	nitial if citation co	onsidered, wheth	er or not citatio	on is in conformance with MP	PEP 609: Dray	w line through citat	ion if not i	conformance				

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

orm PT	0-1	449							t of Commerce emark Office	Atty. Doci 75723-Z.	ket No. 4/JPW/GJG	Serial I 10/037,	
	INI								CITATION	Applicant David B	s altimore et a	ıl.	
		,	(U	se sev	era	l she	et:	s if necess:	ary)	Filing Dat January		Page 2	2 of 44
								U.S. PA	TENT DOCUMEN	NTS			
amine nitial		I	oc	ument	Nun	ber		Date	Name	Class	Subclass	Filing Da	
		Н	$\dashv$	+	-	Н	_			-	ļ	-	
			_		_	ш	MENTS	1					
		Do	cu	ment	Subclass	Tran	slation						
		L			_							Yes	No
		Ш	_		L	Ц			o .				
		Ш	Ц			Ш			<u></u>		L		
		L.					_		ding Author, Title, Da				
/D.G./		mRN	IA Mu	Exp:	res	ssic	n	By Age	"Differential nts Which Blo The Journal o	ck Seco	nd Messen	ger Pa	athway
/D.G./									closporin A I				
									81:5214-5218		,		
/D.G./			y	irox	ycl	1016	C	alcifer	t al., " ol, a New Kidne 71) 230:228-2	ey Hormo			
/D.G.		T F	Ie.	lper	/I	ndu	ce	r Lymph	"1,25-Dihydro: losyte Activit 3032-3035	xyvitam: ty in V	in D, Supp irto¹" Th	resse: e Jour	s Huma
		_			_		_		l., "1α,25-Di				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

Proliferation and Immunoglobulin Production by Normal Human Peripheral Blood Mononuclear Cells", J. Clin. Invest. (1984)

06/15/2008

/D.G./

EXAMINER

74:657-661

/David Guzo/

#### 10037841 - GAU: 1686 Form PTO-1449 Atty. Docket No. U.S. Department of Commerce Serial No. 75723-ZA/JPW/GJG 10/037,341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 23 of 44 January 4, 2002 U.S. PATENT DOCUMENTS Examiner Document Number Date Name Class Subclass Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS Document Number Subclass Translation Date Country Class Yes Nο OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Lipsky, P.E. et al., "The Role of Interleukin 1 in Human B Cell Activation: Inhibition of B Cell Proliferation and the Generation of Immunoglobulin-Secreting Cells By An Antibody Against Human /D.G. Leukocytic Pyrogen' The Journal of Immunology (1983) 130:2708-2714 Männel, D.N., et al., "Inhibition of Nonspecific Tumoricidal Activity by Activated Macrophages with Antiserum Against a Soluble /D.G. Cytotoxic Factor" Infection And Immunity (1981) 33:156-164 Manolagas [1], S.C. et al., "The Antiproliferative Effect of Calcitriol on Human Peripheral Blood Mononuclear Cells" Journal of Clinical Endocrinology and Metabolism (1986) 63:394-400 /D.G./

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Osteoporosis Int (1993) Suppl. 1:S114-116

DATE CONSIDERED

/D.G./

EXAMINER

/David Guzo/

Manolagas [2], S.C. et al., Estrogen, Cytokines, and the Control

of Osteoclast Formation and Bone Resorption In Vitro and In Vivo"

06/15/2008

#### <del>841 - GAU: 16</del>86 Serial No. Form PTO-1449 Atty. Docket No. U.S. Department of Commerce 75723-ZA/JPW/GJG Patent and Trademark Office 10/037,341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 24 of 44 January 4, 2002 U.S. PATENT DOCUMENTS Date Class Examiner Document Number Name Subclass Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS Document Number Date Class Subclass Translation Country Ves No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Matthews [1], Ν., "Human Monocyte Killing of Tumor Cells: Contribution of an Extracellular Cytotoxin" Department of Medical /D.G./ Microbiology (1982) 721-729 Matthews [2], N., "Effect on human monocyte killing of tumour cells of antibody raised against an extracellular monocyte cytotoxin" Immunology (1983) 48:321-327 /D G / Meichle A. et al., "Protein Kinase C-independent Activation of Nuclear Factor KB by Tumor Necrosis Factor" The Journal of Biological Chemistry (1990) 265:8339-8343 /D.G. Mihm [1]. S. And Droge, W., "Intracellular Glutathione Level Controls DNA-Binding Activity of NF-kB-Like Protein(s)" Institute of Immunology and Genetics, German Cancer Research Center, S.A.311

EXAMINER DATE CONSIDERED 06/15/2008 /David Guzo/

/D.G./

/D.Gl/

503

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Mihm [2], S. et al., "Inhibition of HIV-1 replication and NF-KB activity by cysteine and cysteine derivatives" AIDS (1991) 5:497-

#### Form PTO-1449 Atty. Docket No. Serial No. U.S. Department of Commerce 75723-ZA/JPW/GJG Patent and Trademark Office 10/037.341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 25 of 44 January 4, 2002 U.S. PATENT DOCUMENTS Class Examiner Document Number Date Name Subclass Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS Document Number Date Country Class Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Miller, H.R. et al., "Reduction of Nonspecific Fluorescence in /D.G. Respiratory Specimens By Pretreatment with N-Acetylcysteine" Journal of Clinical Microbiology (1986) 24:470-471 Mukaida, N. et al., "Novel Mechanism of Glucocorticoid-Mediated Gene Repression", The Journal of Biological Chemistry (1994) 269:13289-13295 /D.Gl/ Nagasawa, K. et al., "Inductio of Human Malignanat T-Lymphoblastic Cell Lines MOLT-3 and Jurkat by 12-0-Tetradecanov1phorbol-13-Ciochemical, Physical, and Morphological Characterization" Journal of Cellular Physiology (1981) 109:181-/D.G./ 192 al., Norman, A.W. et "1,25-Dihydroxycholecalciferol: Identification of the Proposed Active Form of Vitamin D, in the /D.ds./ Intestine" Science (1971) 173:51-54

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

/D.G./

EXAMINER

86:2336-2340

/David Guzo/

Osborn, L. et al., "Tumor necrosis factor lpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation

of the nuclear factor KB" Proc. Natl. Acad. Sci. USA (1989)

06/15/2008

## U.S. Department of Commerce

Patent and Trademark Office

10037341 GAU: 1636 Atty. Docket No. Serial No. 75723-ZA/JPW/GJG 10/037,341

Applicants

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

and not considered. Include copy of this form with next communication to applicant.

David Baltimore et al. Filing Date Page 26 of 44

January 4, 2002

Examiner Initial	Do	cum	ent N	un	ber	r	Date	Name	Class	Subclass	Filing D		
			П			П					T		
						FC	DREIGN	PATENT DOCU	MENTS				
	 Docu	ıme	ent l	٧u	mb	er	Date	Country	Class	Subclass	Tra	nslation	
											Yes	No	
		от	HER	D	ocı	UME	NTS (Inclu	ding Author, Title, D	ate, Pertinen	t Pages, Etc.)			
/D.G./								., "1,25-Dih nce (1983) 22			Recep	tors i	
/D.G./	Inte	rl	euk	ir	١2	Rec	ceptor	ect of Cyclo Gene Expressi	sporin A on'" The	A and Dexa	metha of Imm	sone o	
/D.G./	huma	(1986) 137:150-154  Reed [2], J.C. et al., "Regulation of c-myc mRNA levels in normal numan lymphocytes by modulators of cell proliferation" Proc. Natl. Acad. Sci. USA (1985) 82:4221-4224											
, 5.0.,										-1-1-1			
/D.G./	 Huma	n '	T L	yπ	nph	ocy	te Act	, "Regulatio iviation by 9:1659-1664	n of Lym 1, 25-D	ihydroxyv:	roduct	ion and	
	 Huma Clin Rigb D <sub>3</sub> O	n ·	T I Inv [2]	es ,	w.	F.C	yte Act 987) 79 C. et a	iviation by	ects of	1,25-Dihy	droxy	vitamin	
/D.G./	Rigb D, o cycl Roed viru	y n e	[2] Humana	ymes , lar ly	W.	F.C F.C F.C s"	yte Act .987) 79 C. et a symphocy The Jou al., "Con n is in	iviation by 0:1659-1664 1., "The Eff	ects of on and inology	1,25-Dihy Prolifera (1985) 13	droxy	vitamin A cel: 9-2286	

## U.S. Department of Commerce

# Patent and Trademark Office

Atty. Docket No. Serial No. 75723-ZA/JPW/GJG 10/037,341

Applicants David Baltimore et al.

Filing Date

Page 27 of 44

## INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

									Januar	4, 2002	_		
							U.S. PA	TENT DOCUMEN	NTS				
Examine r Initial		Doc	cum	ent Nu	nbei		Date	Name	Class	Subclass	Filing D		
	+	L	L	_	╀	L							
					<u></u>	Ļ	OPEICN	PATENT DOCUM	AFNTS	1	1		
	TD	ocu	ıme	nt Nu	ımb		T	Country	Class	Subclass	Trai	slation	
	_	_	_		_	_					Yes	No	
	+	L	Н	Н-	╀	L				-			
		L_	L	Щ.	L	L		ding Author, Title, Da					
/D.G./	Ru	Promyelocytic Leukemia Cells by Tumor Promoters" Science (1979) 204:868-870  Ruben and Rosen, "Suppression of Signals Required for Activation of Transcription Factor NF-kB in Cells Constitutively Expressing											
/D.G./	th	e	HTI	LV-I	Та	x	Protein	" The New Bio	logist	(1990) 2:	894-90	2	
/D.G./	pr	ot	eas	se :	in	n	eurite	t al., "Poss outgrowth of 990) S97-S101	E PC12				
/D.G./		11						"Enhancement o ibitor" Neuros					
/D.G/	Tr	ip	ept	ide	Al	del	et al hyde Pre -1040	., "The Neur tease Inhibit	ite-Ini or on PO	tiating 12h Cells	Effect "J.B	of a	
EXAMINER		/	Dav	rid Guz	20/		DATE CON	SIDERED 0	6/15/2008				
EN LANGER													

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

orm PTC	D-1449						t of Commerce lemark Office	Atty. Doci 75723-Z.		Serial 1 10/037,	
I	NFO	rams	TION	DIS	CL	OSURE (	CITATION	Applicant David B	s Saltimore et a	al.	
		(Use	sever	al sh	eets	s if necess	ary)	Filing Dat January	4, 2002	Page 2	8 of 44
						U.S. PA	TENT DOCUME	NTS			
xaminer nitial	$\perp$	Docum	ent Nu	mber		Date	Name	Class	Subclass	Filing Da	
	+	+	H	+	Н			-	1	+-	
					F	OREIGN	PATENT DOCUM	MENTS	1		
1	D	cum	ent N	umb	er	Date	Country	Class	Subclass	Tran	slation
				_						Yes	No
	-H	_	Н	$\perp$	Ц		-		ļ	$\vdash$	
		+	H	+	Н						
										1 1	
/D.G./	Tra	nein	man,	R.	et on	al., of NF-	uding Author, Title, D 'Characterizat кВ by Activat Biology (199	ion of Med Gluco	Mechanism ocorticoio		
/D.G./	Sch Ele Car	nein ansre lecu nmid emen	man, epre lar t, F	R. essi and	et on C	al., of NF- ellular al., "I Human by Cyc	'Characterizat ĸB by Activat	cion of Med Gluco (5) 15:94 Lear Fac ncy Viru a Sign	Mechanism ocorticoid 13-953 tor Bindi is Enhance	ng to	the K
	Sci Ele Can Jon Sci Nue	neind lecu nmid emen n Be urna	t, Fall of	R. essi and	et on c t he ed ro	of NF- ellular al., "I Human by Cyc. logy (1	'Characterizat KB by Activat Biology (199 Inducible Nucl Immunodeficie losporin A in	cion of Ned Gluco (5) 15:94 Lear Fac ncy Viru a Sign 4041	Mechanism ocorticoid 43-953 tor Bindi as Enhance al-Depend	ng to er in dent M	the kir Cell:
/D.G./	Scl Scl Nuc 17:	neindansrelecu	t, F ts of l of k [1 r Fa 81-1 k [ntly	R. essi and A. es f tocke Vi	et on Con the ed ro	al., of NF-ellular  al., "I  Human by Cyclogy (1  et al.,  KB Activ  R. et ly used	Characterizat  KB by Activat  Biology (199  Inducible Nucl Immunodeficie losporin A in 990) 64:4037-  , "Dithiocarba vation in Inta	tion of hed Gluco (5) 15:94 Lear Fac ncy Viru a Sign 4041 Amates a act Cell	Mechanism coorticole 43-953  tor Bindi ss Enhance al-Depend s Potent s" J. Exp gen inte	ng to er in dent M.  Inhibi. Med.	the KIT Cellianner" tors o: (1992
/D.G./	Sci Ele Can Jon Sci Nuc 17: Sci app tr: 22:	neinnansriecu nmidemen n Be urna nrecclea: 5:11	man, epre lar t, F Blo l of k [1] r Fa 81-1 k [f nntly rript	R. R	et on Con the ed ro	e al., of NF-ellular  al., "I  Human  by Cyc  clogy (1  et al.,  KB Activ  R. et  ly used  actor a	Characterizate RB by Activate Biology (199 conditions of the B	tion of Ped Glucces Sylvan the act Cell  ve oxyvn the ac EMBO Journal of Sylvan the act Cell	Mechanism Decorticole 43-953  tor Bindi as Enhance al-Depend  From J. Exp  gen inter tivation Durnal (1:  athesis Active Fo	ing to er in dent M.  Inhibi. Med.  rmedia of the est of	the KT Cellanner"  tors o (1992  tes a e NF-xl0:2247-

<del>10037841 - GAU: 16</del>36 Form PTO-1449 Atty. Docket No. U.S. Department of Commerce Serial No. 75723-ZA/JPW/GJG Patent and Trademark Office 10/037.341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 29 of 44 January 4, 2002 U.S. PATENT DOCUMENTS Examiner Document Number Date Name Class Subclass Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS Document Number Subclass Translation Date Country Class Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Shirakawa and Mizel. "In Vitro Activation and Translocation of NF-kB Catalyzed by Cyclic AMP-Dependent Protein Kinase and Protein Kinase C", Molecular and Cellular Biology /D.G./ (1989) 9:2424-2430 Siebenlist, U. et al., "Promoter Region of Interleukin-2 Gene Undergoes Chromatin Structure Changes and Confers Inducibility on /D.G. Chloramphenicol Acetyltransferase Gene during Activation of Cells" Molecular and Cellular Biology (1986) 6:3042-3049 St. Ledger, et al., "Factors Associated With Cardiac Morality In /D.G./ Developed Countries With Particular Reference To The Consumption of Wine", Public Health, The Lancet (1979) 1017-1020 Staal, F.J.T. et al., "Intracellular Thiols Regulate Activation

the decoy approach" Nucleic Acids Research (1994) 22:3069-3074

EXAMINER /David Guzo/ DATE CONSIDERED 06/15/2008

of Nuclear Factor kB and Transcription of Human Immunodeficiency Virus", Proc. Natl. Acad. Sci. USA (1990) 87:9943-9947

Tanaka, H. et al., "Sequence-specific interaction of  $\alpha$ - $\beta$ -anomeric

couble-stranded DNA with the p50 subunit of NF-kB: application to

/D.G./

/D.G./

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

				10037	341 - 0	GAU: 16						
Form PT	Patent a  INFORMATION DISCLO (Use several sheets  Information Disclosure of the several sheets  FO  Document Number  OTHER DOCUME!  Thevenin, C. et a Immunodeficiency Specific Inhibit (1990) 2:793-800  Tong-Starksen, Surface Proteins Terminal Repeat"  Tracey, K.J. et prevent septic 330:662-664  Tsoukas, C.D. Immunoregulatory						1 No. 7,341					
	INI								Applica David	nts Baltimore	et a	1.
		(	Use :	seve	ral si	heet	s if necessa	ary)	Filing Januar	Date Y 4, 2002		0 of 44
							U.S. PA	TENT DOCUMEN	TS			
Examiner Initial		D	ocum	ent N	umbe	r	Date	Name	Class	Subclass	Filing Da	
				Ш								
	Document Num						OREIGN	PATENT DOCUM	IENTS			
		Doc	ume	ent N	lum	ber	Date	Country	Class	Subclass	Trar	slation
											Yes	No
			T	П	Т	Т						
			от	HER	DOC	UM	ENTS (Inclu	ding Author, Title, Da	te, Pertinen	Pages, Etc.)		
/D.G./		Imm Spe	uno cif	def ic	ici Inh	enc ibi	y Virus	Long Termina	1 Repea	t by Oka	daic A	Acid, a
/D.G./		Sur	fac	e F	rot	eir	ns, TCR	CD3 And CD28	, Acti	vates The	HIV-	1 Long
/D.G./		pre	ven	t s	ept							
/D.G./								, %1,25-Dih ne" Science (1				Novel
/D.G./		Waage and Bakke, "Glucocorticoids tumour necrosis factor by lipopl monocytes" Immunology (1988) 63:299						ysaccharide-stimulated hum				

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

06/15/2008

DATE CONSIDERED

EXAMINER

/David Guzo/

#### 10037341 - GAU: 1636 Atty. Docket No. Form PTO-1449 U.S. Department of Commerce Serial No. 75723-ZA/JPW/GJG 10/037,341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Page 31 of 44 Filing Date January 4, 2002 U.S. PATENT DOCUMENTS Examiner Document Number Date Class Subclass Name Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS Document Number Date Country Subclass Translation Class Yes Nο OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Weissmann, G., "Aspirin: After more than 200 years, the mechanisms by which this venerable drug and its relatives achieve their wide range of effects have yet to be fully elucidated" Scientific /D.G. American Journal (1991) pp. 84-90 Physicians' Desk Reference 1970 24th Edition /D.G. Physicians' Desk Reference 1980 34th Edition /D.G. Physicians' Desk Reference 1985 39th Edition /D.G

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance

06/15/2008

EXAMINER

/David Guzo/

and not considered. Include copy of this form with next communication to applicant.

#### Atty. Docket No. Serial No. Form PTO-1449 U.S. Department of Commerce 75723-ZA/JPW/GJG Patent and Trademark Office 10/037,341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 32 of 44 January 4, 2002 U.S. PATENT DOCUMENTS Examiner Document Number Date Name Class Subclass Filing Date Initial f Appropriate FOREIGN PATENT DOCUMENTS Document Number Date Country Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) June 28, 2007 Deposition of Lynn Corcoran, Ph.D., Pages 1-109, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. /D G / Civil Action No. 06-259-MPT July 10, 2007 Deposition of Roger Gregoire Clerc, Ph.D., Pages 1-201, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. /D.G./ Del. Civil Action No. 06-259-MPT August 7, 2007 Videotaped Deposition of Louis M. Staudt, M.D. Ph.D., Pages 1-275, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT /D.G./ August 20, 2007 Videotaped Deposition of Patrick A. Baeuerle. Ph.D., Vol. I-II, Amgen, Inc. et al. v. Ariad Pharmaceuticals. /D.G./ Inc. et al., D. Del. Civil Action No. 06-259-MPT June 2007 Wyeth's Response To Ariad's First 29, Set

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

/D.G./

EXAMINER

/David Guzo/

Interrogatories (Nos. 1-25), Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT

06/15/2008

/D.G./ EXAMINER

/David Guzo/

U.S. Department of Commerce

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Patent and Trademark Office

Atty. Docket No. Ser Serial No.

75723-ZA/JPW/GJG 10/037,341

Applicants David Baltimore et al. Filing Date Page 33 of 44

January 4, 2002

#### U.S. PATENT DOCUMENTS Examiner Document Number Date Name Class Subclass Filing Date if Appropriate Initial

		FOREIG	PATENT DOCUMEN	TS										
	Document Number	Date	Country	Class	Subclass	Tra	inslation							
						Yes	No							
		1.												
	OTHER DOCU	MENTS (Inclu	ding Author, Title, Date	, Pertinent	Pages, Etc.)									
/D.G./	Entities' Second	d Set Of	e Institutions' R Interrogatories, L., D. Del. Civil	Amgen,	Inc. et	al.								
/D.G./	August 17, 2007 Wyeth's Supplemental Responses To Ariad's First Set Of Interrogatories (Nos. 1-25), Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT													
/D.G	First Set Of In	nterrogato	Second Set of Scries (Nos. 1-25)	, Amgen	, Inc. et	al.								
/D.G./	Annual Meeting,	J. Am. Med.	Assoc. (1963) 18	3:166-1	59									
D.G./	Baeuerle and Baltimore, "IKB: A Specific Inhibitor of the NF-KB Trans Factor", Science (1988a) 242:540-546													
			ctivation of DNA-H e NF-kB Transcript											

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

/David Guzo/

DATE CONSIDERED

	***				Patent	and Tradem:	ark Office	Atty. Docket No. 75723-ZA/JPW/GJG Applicants		10/037,	341
	IN					OSURE CIT			ltimore et al.		
		(U	se se	ver	al sheet:	s if necessary	)	Filing Date January		Page :	34 of 44
							TENT DOCUMENT				
Examiner Initial	1	Docu	ment	Num	ber	Date	Name	Class	Subclass	Filing Da	
	+	┝	╀	⊢	++-			-		-	
		Щ.	<u> </u>	_	ш_	FORFICA	PATENT DOCUME	NTS		<u> </u>	
		Docum	ent	Nu	mber	Date	Country	Class	Subclass	Tra	nslation
										Yes	No
					П						
			L	L	Ш						
		01	HE	R D	OCUM	ENTS (Inclu	ding Author, Title, Da	ate, Pertinen	t Pages, Etc.)		
/D.G./	Tra	anscr	ipt	ior	n Fact	or Involv	"Phorbol-ester- res Dissociation Spring Harbor	of an A	pparently (	ytopla	smic NF-
	+										
/D.G./	the	e Pro	omo	ter	of '	The Mouse	ng of a Nuclear : H-2K <sup>b</sup> Class I ogy (1987) 7:30	Major	o a Regulate Histocompat	ory Sec	quence in y Gene",
	B = 1	l t i mo	<b>~</b>	_	*Tn	tracellul	ar immunization	" Natura	(1000) 225	. 205 . 2	96
/D.G./	-	CIMO	16,	<i>D</i> .	, 111	cracerrur	ar mmanrzacion	, Nacure	(1900) 333	1:393-3	. 50
/D.G./	Mit Enl	ogen	-In r E	duc	ced Ac	tivation	e Immunosuppres of the Interkend NF-AT1", Mol	eukin-2 E	romoter an	d the	Isolated
/D.G./	int	erfe	ron	re	et espons 9-1144	e sequence	gamma-interfero e of the MHC cla	on-induce iss I gene	d factor t	hat b	inds the D Journal
EXAMINER	/D	avid G	uzo	/		DATE CONSII	DERED 06/15/2	2008			

Paten					Commerce ark Office	75723-Z	A/JPW/GJG	Serial N 10/037,3	
INFO						Applicants David Ba			
	(Us	e sever	al shee	ts if necessary	7)			Page 3	5 of 44
				U.S. P.	ATENT DOCUMENT	S			
D	ocum	ent Num	ber	Date	Name	Class	Subclass		
++	Н	$\vdash$	H			+	<del> </del>	+	
		Ц	1	FOREIG	N PATENT DOCUME	NTS		.1	
Do	cum	ent Nu	nber	Date	Country	Class	Subclass	Tra	nslation
								Yes	No
Ш	L								
44	┺	Н.	Ш	ļ				1	
	上			,					
Activ	ati	Lon of	Both						
Expre	essi	Lon i	n a	Chronical	y Infrected Hum	of Human man T Ce	n Immunodef ll Clone",	iciency The Jo	Virus-
Macro	pha	iges a	are A	ccompanie	by Early And T	ransient	Increase or	Decre	ase in c-
in M	acr	ophag	es: 1	nvolvemen	t of Four kB-Li	ke Motif	s and of C	onstitu	tive and
-		/David	Guzo	DATE CONSI	DERED 06/1	5/2008			
	Bohn: Activing Expression Colling Induction Crossin Induction Indu	Docum  Docum  Docum  OT  Sohnlein Activat: (1988): Express: Immunol: Collart Macrophi FOS Gent  Collart Inducib  Cross, Immunog	Document Num  OTHER D  Bohnlein E. Activation oid  (1988) 53:82*  Clouse, K.A. Expression i. Immunology (i. Collart, M.A. in Macrophage a FOS Gene Trai  Collart, M.A. in Macrophage Inducible For  (ross, S.L. Immunoglobul:	Document Number  Document Number  OTHER DOCUM  Dohnlein E. et al Activation of Both  (1988) 53:827-836  Clouse, K.A. et a  Expression in a c  Immunology (1989)  Collart, M.A. et Macrophages are A. FOS Gene Transcri  Collart, M.A. et ain Macrophages: I Inducible Forms of  Cross, S.L. et  Immunoglobulin K.  /David Guzo.	Use several sheets if necessary  U.S. P.  Document Number Date  FOREIG!  Document Number Date  OTHER DOCUMENTS (Incle Bohnlein E. et al., "The Activation of Both the Inte (1988) 53:827-836  Clouse, K.A. et al., "Mond Expression in a Chronicall Immunology (1989) 142:431-4  Collart, M.A. et al., "Mod Macrophages are Accompanied FOS Gene Transcription", Ti  Collart, M.A. et al., "Regu in Macrophages: Involvemen Inducible Forms of NF-KB", I  Cross, S.L. et al., "Fur Immunoglobulin K and IL-2 F  (David Guzo) DATE CONSI	Document Number   Date   Name	David Barling DiscLosure CITATION (Use several sheets if necessary)   David Barling Data	David Baltimore et al.	David Baltimore et al.   Page 3   Page 4   Page 4   Page 3   Page 3   Page 3   Page 3   Page 4   Page 4   Page 3   Page 4   Page 4   Page 5   Page 5   Page 5   Page 5   Page 5   Page 6   Page 7   Pa

									1003	7341 - (	GAU: 16		
Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office								Atty. Docket No. Serial No. 75723-ZA/JPW/GJG 10/037,341					
	IN					LOSURE CIT		Applicants  David B	altimore et al.				
			(Use	sever	al shee	ets if necessary	···	Filing Date January		Page 3	6 of 44		
						U.S. PA	TENT DOCUMEN	rs		,			
Examiner Initial	$\perp$	Do	ocum-	ent Num	ber	Date	Name	Class	Subclass	Filing Date if Appropriate			
									1		-		
		_				FOREIGN	PATENT DOCUM	ENTS	1	1			
		Document Number			mber	Date	Country	Class	Subclass	Translation			
										Yes	No		
		$\perp$			Ш								
		┺	Ш		ш								
		$\perp$	Ш	丄	ш	<u> </u>			1				
							ding Author, Title, I				-		
/D.G./	Tı	ans	cri	l. et ption	al. 1 Fac	, "Rel-Ass tors", Sci	ociated pp40: ence (1991) 25	An Inhibi 3:1268-127	tor of the	Rel F	amily of		
/D.G./	De Sa 24	lic	M.J yli	. et c aci	al., d in	"Maintenar high doses	nce of remissions by mouth", Br	n in ulcer itish Medi	ative colit	is with (1983)	5-amino 287:23-		
/D.G./	Ar Vi	ıtim	icr	obial d In-	l Age	nts on End	"Effects of I otoxin Release candinavian Jo	from Gram	-negative E	Bacteria	: An In-		
/D.G./	re	n, qui	red	for	ng an	nd Maniatis an β-inter	, T., "Two dif feron gene re	ferent virgulation",	rus-inducib The EMBO	le elem Journa	ents are l (1989)		
/D.G./	se	par	ate	d zir	ac fi		, T., "A DNA-bi s that recogniz						

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

06/15/2008

DATE CONSIDERED

EXAMINER

/David Guzo/

#### Form PTO-1449 Atty. Docket No. Serial No. U.S. Department of Commerce 75723-ZA/JPW/GJG 10/037,341 Patent and Trademark Office Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Page 37 of 44 Filing Date January 4, 2002 U.S. PATENT DOCUMENTS Class Examiner Document Number Date Name Subclass Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS Document Number Date Country Class Subclass Translation Yes OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Fan, Chen-Ming and Maniatis, T., "Generation of p50 subunit of NFkB by processing of pl05 through an ATP-dependent pathway", Nature /D.G./ (1991) 354:395-398 Friedman, A.D. et al., "Expression of a truncated viral transactivator selectively impedes lytic infection by its cognate /D.G./ virus", Nature (1988) 335:452-454 Gehrt, A. Et al., "Cycloepoxydon, 1-Hyrdoxy-2-hycroxymethyl-3pent-1-enylbenzene and 1-Hydroxy-2-hydroxymethyl-3-pent-1, 3-/D.G./ dienylbenzene, New Inhibitors of Eukaryotic Signal Transduction", The Journal of Antibiotics (1998) 51:455-463 Goldfelf, A.E. and Maniatis, T., "Coordiante viral induction of tumor necrosis factor $\alpha$ and interferon $\beta$ cells and monocytes", /D.G./ Proc. Natl. Acad. Sci. USA (1989) 86:1490-1494

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

Sci. USA (1990) 87:9769-9773

/David Guzo/

DG/

EXAMINER

Goldfeld, A. E. et al., "Human tumor necrosis factor lpha gene regulation by virus and lipopolysaccharide", Proc. Natl. Acad.

06/15/2008

## U.S. Department of Commerce

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Patent and Trademark Office

Atty. Docket No. Serial No. 75723-ZA/JPW/GJG 10/037,341

Applicants David Baltimore et al. Filing Date Page 38 of 44

January 4, 2002

#### U.S. PATENT DOCUMENTS Examiner Date Document Number Name Class Subclass Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS Document Number Date Class Subclass Country Translation Yes OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Goodbourn, S. And Mantiatis, T., "Overlapping positive and negative regulatory domains of the human β-interferon gene", Proc. /D.G./ Natl. Acad. Sci. USA (1988) 85:1447-1451 Haskill, S. et al., "Characterization of an Immediate-Early Gene Induced in Adherent Monocytes That Encodes IxB-like Activity", /D.G./ Cell (1991) 65:1261-1289 Horuk, R., "A rapid and direct method for the detection and /D.G./ quantification of interleukin-1 receptors using 96 well filtration plates", Journal of Immunological Methods (1989) 119:255-258 Hurley, J.C. et al., "Antibiotic-Induced Release of Endotoxin in Chronically Bacteriuric Patients", Antimicrobial Agents /D.G./ and Chemotherapy (1991) 35:2388-2394 Keller, A.D. and Maniatis, T., "Identification of an inducible factor that binds to a positive regulatory element of the human /D.G./ β-interferon gene", Proc. Natl. Acad. Sci. USA (1988) 85:3309-3313 Kerr, L.D. et al., "The Rel-associated pp40 protein prevents DNA /D.G. binding of Rel and NF-kB: relationship with IkBB and regulation by phosphorylation", Genes and Development (1991) 5:1464-1476 EXAMINER /David Guzo/ DATE CONSIDERED 06/15/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form P									t of Commerce lemark Office	Atty. Doc 75723-Z	ket No. A/JPW/GJG	7341 - CAU: 16 Serial No. 10/037,341		
	IN	FOI							CITATION	Applicant David E	s Baltimore et a	ıl.		
			(U	se s	ever	al s	heet	s if necessa	ary) 	Filing Da Januar	te y 4, 2007	Page 3	9 of 44	
								U.S. PA	TENT DOCUME	NTS				
Examine Initial			Doc	ume	nt Nu	mbe	,	Date	Name	Class	Subclass	Filing Date if Appropriate		
		Н	-	Н	+	+-	╁	-		-	-	<del> </del>		
7							F	OREIGN	PATENT DOCUM	MENTS	1	1		
		D	ocu	mei	at N	uml	oer	Date	Country	Class	Subclass	Translation		
		Ц,		_,		_	_					Yes	No	
		Н		4	$\perp$	$\perp$	1							
	L	Ш		$\perp$						L	L			
-		la-							ding Author, Title, D					
/D.G./		Mo:	rta	ali	tу	In	De.	veloped	al., "Facto Countries Wit The Lancet (1	h Parti	cular Refe	Vith erence	Cardia To The	
/D.G.		De:	te	cmi	ne	Tr	ans	al., "P scriptio -1577	rotein-Bindin onal Activity	g Sites and I	in Ig Ge nducibili	ne En	hancer: Science	
/D.G./		sp:	Lee	en:	Nι	ıcl	eot	ide sti	"NF-kB prote imulation and USA (1988) 8	bindir	ng site s	from	bovin	
		Ger	ıe	Re	gul	ati	ion	Reveals	"The Involvem s Its Role as Cell (1989) 5	Widely	Inducible	β-Inte	erferon	
/D.G./		519	jna	rT_	IIa				Leii (1989) 5	7:287-2	94			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

06/15/2008

DATE CONSIDERED

/D.G./ XAMINER

/David Guzo/

#### Atty. Docket No. Form PTO-1449 U.S. Department of Commerce Serial No. 75723-ZA/JPW/GJG Patent and Trademark Office 10/037.341 Applicants INFORMATION DISCLOSURE CITATION David Baltimore et al. (Use several sheets if necessary) Filing Date Page 40 of 44 January 4, 2002 U.S. PATENT DOCUMENTS Examiner Date Subclass Document Number Name Class Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS Document Number Date Subclass Country Class Translation Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Logeat, F. et al., "Inhibition of transcription factors belonging to the rel/NF-xB family by a transdominant negative mutant", The /D.G./ EMBO Journal (1991) 10:1827-1832 Mauxion, F. et al., "Comparison of constitutive and inducible transcriptional enhancement mediated by KB-related sequences: Modulation of activity in B cells by human T-cell leukemia virus /D.G./ type I tax gene", Proc. Natl. Acad. Sci. USA (1991) 88:2141-2145 Mauxion, F. And Sen, R., "Alteration of a Single Nucleotide Allows Efficient Binding of H2TF1/KBF1 to the Immunoglobulin K Enhancer /D.G./ B Motif", Molecular and Cellular Biology (1989) 9:3548-3552

EXAMINER

/D.G.

/David Guzo/

160:891-895

DATE CONSIDERED

06/15/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Mustafa, M.M. et al., "Increased Endotoxin and Interleukin-18 Concentrations in Cerebrospinal Fluid of Infants with Coliform

Meningitis and Ventriculitis Associated with Intraventricular Gentamicin Therapy", The Journal of Infectious Diseases (1989)

								of Commerce emark Office	Atty. Doc 75723-Z.	ket No. A/JPW/GJG	341 - GAU: 160 Serial No. 10/037,341		
I	NFOI	RMA	TIC	ON 1	DIS	CL	OSURE C	ITATION	Applicant David B	s altimore et al.			
		(Use	sev	vera	l sh	eets	if necessa	ry)	Filing Dat	te y 4, 2002	Page ·	41 of 44	
							U.S. PAT	TENT DOCUME	NTS				
Examiner nitial	$\downarrow$	Docun	nent	t Nun	nber	_	Date	Name	Class	Subclass	Filing Date if Appropriate		
		+	$^{+}$	+									
						F	DREIGN I	PATENT DOCU	MENTS				
	D	ocum	ent	t Nu	mbe	er	Date	Country	Class	Subclass	Translation		
	$\perp$		_	_		4						No	
	$\perp$		╀	4	Ш	4							
	$\perp$		$\perp$	_	Ш	4					1		
			L		Ш								
								ding Author, Title, D					
/D.G./	ac	tiva	ιte	es e	xp	res	altimore sion of 26:711-7	human immuno	nducible odeficie	transcri ncy virus	ption in T	facto: cells"	
/D.G./	In	duci	bl	Le	Tra	ns	criptio:	NF-ĸB-Bindin n in Nonlym 8:3526-3531	phoid C	ediates Ph ells", Mo	norbol	l Ester lar and	
/D.G./	1,:	gby, 25-E	ìh	ıydı	OX	et	al., " tamin D	Inhibition o	f T Lymp 1)", J.	hocyte Mi Clin. In	togen vest.	(1984	
/D.G./	Hui	nan	т	Ly	mph	loc	yte Act	The Effects of ivation And of Immunolog	Prolife	ration: A	A Cel	l Cycle	
/D.G./	of	IL-	-2	Re	cep	to	, "Cell r Gene !41:89-9	ular Transcr Expression    2	iption F by HTLV-	actors and tax Ge	nd Reg ne Pr	ulation oduct",	
EXAMINER				f Guz		ı	DATE CONS	IDERED	06/15/200	8			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

								of Commerce emark Office		ocket No. A/JPW/GJG	Serial No. 10/037,341				
	INF						LOSURE C		Applica David	nts Baltimore	et a	1.			
(Use several sheets if necessary)									Filing Date Page 42 of 44 January 4, 2002						
							U.S. PAT	ENT DOCUMEN	NTS						
Examiner Initial		Do	cum	ent N	iumb	umber Date Name				Subclass	Filing Date if Appropriate				
	1 100				$\perp$										
						F	OREIGN F	PATENT DOCUM	MENTS						
		Doc	um	ent l	Num	ber	Date	Country	Class	Subclass	Translation				
											Yes	No			
			Τ	П	Т										
			от	HER	DO	CUM	ENTS (Includ	ling Author, Title, Da	te, Pertinen	t Pages, Etc.)					
/D.G./								"Proteins co							
/D.G./		Schr secc	ec	k, me	R. sse	an nge	d Baeuer ers", Tre	rle, P., "A ends in Cell	role fo Biology	r oxygen (1991) 1	radio :39-42	cals as			
/D.G./		Sen, the	R Im	. ar mun	nd E ogl	alt obu	imore, D	., "Multiple ncer Sequence	Nuclear es", Cel	Factors 1	Intera 46:70	ct with			
/D.G./	- 1	Enha	nc	er-	Bin	din	altimore, ng Protei: 921-928	D., "Induc n NF-кВ by а l	ibility Posttran	of K Im	munog L Mech	lobulin anism",			
/D.G./	, þ	Duri	ng	Ant	tib:	iot	ic Therap	n, K.A., "Ki by For Experim Infectious	ental Gr	am-Negat:	ive Ba	cterial			

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

06/15/2008

DATE CONSIDERED

EXAMINER

/David Guzo/

## U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. Serial No. 75723-ZA/JPW/GJG 10/037,341

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Applicants
David Baltimore et al.
Filing Date Page 43 of 44

	(U	se:	seve	ral	shee	ts if necess	ary)	Filing Janua:	Date ry 4, 2002		43 of 44	
						U.S. PA	TENT DOCUMEN	NTS				
Examiner Initial	Doe	cum	ent N	Num	ber	Date	Name	Class	Subclass		Filing Date if Appropriate	
FFTI	3170							101				
					]	FOREIGN	PATENT DOCUM	MENTS				
	Docu	ıme	ent l	Nur	aber	Date	Country	Class	Subclass	Tra	nslation	
		_								Yes	No	
			Ш									
		от	HEF	R DC	CUN	IENTS (Incl	uding Author, Title, Da	ate, Pertinen	t Pages, Etc.)			
/D.G./							G.P., "Search cience (1990)			Ligar	nds with	
/D.G./	Arth Olig	ri od	tis eox	yn	y ] ucle	n Vivo	"Suppressed S Transfection As A Gene The	of Nuc	lear Fact	or K	B Decoy	
/D.G./	acti	va	ted	l h	uma	n lympho	down-regulati ocytes by 1,25	-dihydı				
-												
/D.G./	Diss	oc.	iat	e 1	he	Complex	le, P.A., "Pu: of the NF-кВ 90) 61:255-26	Transcr	Human IkB iption Fac	Can ctor w	Rapidly with Its	
	_											
/D.G./		on	s A	١dj			dentification he Human β-Ir					
						_						
EXAMINER	/	Dav	rid G	iuzo	/	DATE CON	SIDERED 06/1	5/2008				
							on is in conformance with M cation to applicant.	IPEP 609: Drav	v line through citati	on if not i	n conformance	

## U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 75723-ZA/JPW/GJG

Serial No. 10/037,341

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Applicants
David Baltimore et al.
Filing Date Page 44 of

	(	Use	sever	al shee		Filing Date Page 44 of January 4, 2002					
					U.S. PAT	TENT DOCUME	ENTS				
Examiner Initial	D	ocum	ent Ni	ımber	Date	Date Name		Subclass		Filing Date if Appropriate	
	864										
				1	FOREIGN	PATENT DOCU	MENTS				
	Do	cum	ent N	umber	Date	Country	Class	Subclass	Tra	nslation	
									Yes	No	
		ОТ	HER	DOCUM	IENTS (Inclu	ding Author, Title, I	Date, Pertinen	t Pages, Etc.)			
/D.G./	Judg	eme	nt Per	nding R	eexaminatio	upport of Eli Lilly on or For Settleme n Civil Case 02 C	nt of Form	of Final Judge	ement, I	Document	
/D.G./	Entr	August 22, 2007 Reply Memorandum In Support of Eli Lilly And Company's Motion To Stay Entry of Judgement Pending Reexamination or For Settlement of Form of Final Judgement, Document 414, filed 08/22/2007, pgs. 1-11, including Exhibits 2-6 in Civil Case 02 CV 11280 RWZ									
/D.G./				2007 F RWZ	inal Judgen	nent, Document 41	17, filed 09/	10/2007, pgs.	1-5 in (	Civil Case	
/D.G./	As A	Ma	tter C	f Law	Or, In The A	n In Support of De Alternative, A New Civil Case 02 CV	v Trial, Doci	ument 420, fil			
/D.G./	Stay	Entr ment	y Of , Doo	Judgme cument	nt Pending	ra P. Masurovsky Reexamination Or 7/16/2007, pgs. 1-	r For Settler	nent Of Form	of Fina	1	
/D.G./	July 26, 2007 Plaintiffs' Opposition To Lilly's Motion To Stay Entry Of Judgment Pending Reexamination or for Settlement of Form of Final Judgement, Document 411, filed 07/26/2007, pgs. 1-11, including Exhibit 2 in Civil Case 02 CV 11280 RWZ									ending	
EXAMINER	/0	avid	Guzo	/	DATE CONS	SIDERED	06/15/200	)8			

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.